260 related articles for article (PubMed ID: 37280381)
1. [Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].
Klose G; Gouni-Berthold I; März W
Inn Med (Heidelb); 2023 Sep; 64(9):895-906. PubMed ID: 37280381
[TBL] [Abstract][Full Text] [Related]
2. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
Kim K; Ginsberg HN; Choi SH
Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
[TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
4. Current and future trends in the treatment of dyslipidemias.
Vrablík M
Vnitr Lek; 2019; 65(10):643-650. PubMed ID: 31906686
[TBL] [Abstract][Full Text] [Related]
5. New Trends in Dyslipidemia Treatment.
Jang AY; Lim S; Jo SH; Han SH; Koh KK
Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
[TBL] [Abstract][Full Text] [Related]
6. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname MH; Rocha VZ; Santos RD
Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
[TBL] [Abstract][Full Text] [Related]
7. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
8. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
Li S; Zhao X; Zhang Y; Zhu CG; Guo YL; Wu NQ; Xu RX; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
Oncotarget; 2017 Feb; 8(7):12333-12341. PubMed ID: 27713142
[TBL] [Abstract][Full Text] [Related]
9. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
10. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
11. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
12. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
Rached F; Santos RD
Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
15. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
17. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
18. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
19. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
Feng X; Zhang L; Xu S; Shen AZ
Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
[TBL] [Abstract][Full Text] [Related]
20. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
